Literature DB >> 23453135

IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses.

Willem van de Veen1, Barbara Stanic, Görkem Yaman, Marcin Wawrzyniak, Stefan Söllner, Deniz G Akdis, Beate Rückert, Cezmi A Akdis, Mübeccel Akdis.   

Abstract

BACKGROUND: IL-10-producing regulatory B cells suppress immune responses, and lack of these cells leads to exacerbated symptoms in mouse models of chronic inflammation, transplantation, and chronic infection. IgG4 is a blocking antibody isotype with anti-inflammatory potential that is induced in human high-dose antigen tolerance models.
OBJECTIVE: We sought to characterize human inducible IL-10-secreting B regulatory 1 (BR1) cells and to investigate their immunoregulatory capacity through suppression of cellular immune responses and production of anti-inflammatory immunoglobulins.
METHODS: Highly purified IL-10-secreting B cells were phenotypically and functionally characterized by means of whole-genome expression analysis, flow cytometry, suppression assay, and antibody production. B cells specific for the major bee venom allergen phospholipase A2 (PLA) were isolated from beekeepers who displayed tolerance to bee venom antigens and allergic patients before and after specific immunotherapy.
RESULTS: Human IL-10+ BR1 cells expressed high surface CD25 and CD71 and low CD73 levels. Sorting of CD73-CD25+CD71+ B cells allowed enrichment of human BR1 cells, which produced high levels of IL-10 and potently suppressed antigen-specific CD4+ T-cell proliferation. IgG4 was selectively confined to human BR1 cells. B cells specific for the major bee venom allergen PLA isolated from nonallergic beekeepers show increased expression of IL-10 and IgG4. Furthermore, the frequency of IL-10+ PLA-specific B cells increased in allergic patients receiving allergen-specific immunotherapy.
CONCLUSION: Our data show the characterization of IL-10+ BR1 cells and in vivo evidence for 2 essential features of allergen tolerance: the suppressive B cells and IgG4-expressing B cells that are confined to IL-10+ BR1 cells in human subjects.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23453135     DOI: 10.1016/j.jaci.2013.01.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  185 in total

1.  Glycomacropeptide administration attenuates airway inflammation and remodeling associated to allergic asthma in rat.

Authors:  Nuria Renata Roldán; Mariela Jiménez; Daniel Cervantes-García; Estefanía Marín; Eva Salinas
Journal:  Inflamm Res       Date:  2016-01-11       Impact factor: 4.575

Review 2.  Modified allergens and their potential to treat allergic disease.

Authors:  Laurian Jongejan; Ronald van Ree
Journal:  Curr Allergy Asthma Rep       Date:  2014-12       Impact factor: 4.806

Review 3.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 4.  Immunology of IgG4-related disease.

Authors:  E Della-Torre; M Lanzillotta; C Doglioni
Journal:  Clin Exp Immunol       Date:  2015-06-08       Impact factor: 4.330

5.  Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs.

Authors:  Cezmi A Akdis; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

6.  Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects.

Authors:  Tetsuya Terada; Masaya Matsuda; Miki Inaba; Junpei Hamaguchi; Naoki Takemoto; Yusuke Kikuoka; Yuko Inaka; Harumi Sakae; Kennosuke Hashimoto; Hayato Shimora; Kazuyuki Kitatani; Ryo Kawata; Takeshi Nabe
Journal:  Inflamm Res       Date:  2021-04-09       Impact factor: 4.575

Review 7.  The use of biologics for immune modulation in allergic disease.

Authors:  Willem van de Veen; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

8.  Insulin-like growth factor-2 enhances functions of antigen (Ag)-specific regulatory B cells.

Authors:  Xiao-Rui Geng; Gui Yang; Meng Li; Jiang-Ping Song; Zhi-Qiang Liu; Shuqi Qiu; Zhigang Liu; Ping-Chang Yang
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

Review 9.  Human Helminths and Allergic Disease: The Hygiene Hypothesis and Beyond.

Authors:  Helton C Santiago; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2016-08-29       Impact factor: 2.345

10.  Peptide Immunotherapy; short but long lasting?

Authors:  Elizabeth J Simms; Ijlal Syed; Christopher Rudulier; Mark Larché
Journal:  Curr Treat Options Allergy       Date:  2015-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.